Agilus Diagnostics announces the launch of its Pharmacogenomics Testing Service. This innovative service aims to empower healthcare providers and patients with vital insights into how individual genetic profiles influence medication effectiveness and safety, paving the way for a more personalised approach to treatment.
Pharmacogenomics (PGx) testing can offer valuable insights for patients who are either starting or already taking medications for various conditions. By analysing the genetic makeup, PGx testing can help healthcare providers to determine suitable and effective treatment options. For those who have struggled to find medications that effectively manage their symptoms, PGx testing could be particularly beneficial in guiding personalised treatment plans.
Agilus’ pharmacogenomics panel based on whole exome sequencing covers 59 PGx genes and 194 drugs. It also covers 32 genes associated with clinical annotations and dosing guidelines. Its reporting is based on the standard dosing guidelines, incorporating 191 CPIC, 108 DPWG and many others. The drug genomics panel includes 17 specialities, like cancer, cardiovascular disorders, depression, neurology, gastroenterology, paediatrics, endocrinology, immunosuppressant medications etc.
Commenting on the initiative, Dr Anand K, MD and CEO of Agilus Diagnostics said, “As the Global Pharmacogenomics market is projected to reach $ 5.8 billion by 2028, we are excited to be at the forefront of this revolution in personalised medicine.”
Dr Ravneet Kaur, Medical Geneticist, Agilus Diagnostics, emphasised the importance of matching the right drug to the right patient at the correct dosage. “Far too many patients suffer from adverse drug reactions or ineffective treatments. Drug Genomics offers a cost-saving solution by reducing hospital visits and readmissions through personalised treatment plans. Recent studies on the Indian population show that each individual carries eight pharmacogenomics variants that affect treatment selection and dosage.” Dr Kaur adds that addressing these genetic differences, can improve patient outcomes and ensure safer, more effective therapies.
Talking about the impact of genetic variations in psychiatric medications, Dr Samir Parikh, Chairperson, Fortis National Mental Health Program, Fortis Healthcare and Advisor, Pharmacogenomics, Agilus Diagnostics said “By utilising pharmacogenomic testing, psychiatrists can determine whether a patient carries specific genetic variants that affect drug metabolism. This invaluable information enables clinicians to select medications that are more likely to be effective and adjust dosages to minimise the risk of side effects. This personalised approach not only enhances symptom management but also improves patient adherence to treatment.”
As we continue to explore the genetic underpinnings of psychiatric disorders and treatment responses, pharmacogenomics can prove to be beneficial in psychiatry. Reportedly, this approach can hold the promise of better patient outcomes and a more nuanced and individualised understanding of mental health.